Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- HUMAN RESOURCES NEWS IN BRIEF
March 27, 2006
- Baraclude More Beneficial than Lamivudine for CHB
March 27, 2006
- Taisho to Increase Focus on Health & Beauty Business
March 27, 2006
- Sales Up 9.7% in 2005 Targeting Diabetes: Novo Nordisk
March 27, 2006
- US Study Shows Good Results for NM-702 Against ASO
March 27, 2006
- SELF-MEDICATION NEWS IN BRIEF
March 27, 2006
- Takeda Announces License Agreement for Tavocept in Japan
March 27, 2006
- 3 Bioventures to Jointly Develop Anticancer Agents
March 27, 2006
- MEDICAL DEVICE NEWS IN BRIEF
March 27, 2006
- NPhA Criticizes Takeda's Attitude toward Chain Pharmacies
March 27, 2006
- Korosho Submits Proposed GL for Animal Studies
March 27, 2006
- Hokuyaku, Takeyama to Integrate Management
March 27, 2006
- R&D NEWS IN BRIEF
March 27, 2006
- Industry Must Reject Price Reductions Not Based on Market Prices: JPMA President
March 20, 2006
- Pharmacies to Play a Greater Role: JPA Vice President
March 20, 2006
- Takeda Asks Wholesalers Not to Accept Proposals of Bundling from Pharmacy Chains
March 20, 2006
- JPA Presents Petition Regarding New OTC Drug Marketing System
March 20, 2006
- REGULATORY NEWS IN BRIEF
March 20, 2006
- Bill to Amend PAL Approved by Cabinet
March 20, 2006
- Kowa, Nikken Chemicals to Integrate Operations on Oct. 1
March 20, 2006
ページ
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…